PROTECT (Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial): a randomized, double-blind clinical trial of diltiazem versus atenolol in secondary prophylaxis post non-Q wave myocardial infarction.

Shaun G. Goodman(University of Toronto), A. Langer, Christopher Thompson(Toronto General Hospital), David Massel, E. J. Stanton, Jules Y.T. Lam, James Nasmith, CA Hill, W. Warnica, Lyall Higginson(University of Ottawa), Albert Fung, Iqbal Bata, John McCans

PubMed

November 1, 1996

Cited by 3

Related Papers

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

|New England Journal of Medicine|2018|3.5k

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

|The Lancet|2018|1.8k

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

|Circulation|2008|757

Intravenous Platelet Blockade with Cangrelor during PCI

|New England Journal of Medicine|2009|643

Platelet Inhibition with Cangrelor in Patients Undergoing PCI

|New England Journal of Medicine|2009|618